President of the Novartis Institutes for BioMedical Research
Jay Bradner is President of the Novartis Institutes for BioMedical Research (NIBR), the company’s innovation engine. He leads thousands of scientists at research sites around the world in an effort to discover life-changing medicines for patients.
Jay’s bold ambition is for NIBR to go after the highest hanging fruit in drug discovery, including targets previously deemed impossible to reach, or “undruggable.” To support this research, NIBR has invested in powerful approaches and technologies such as targeted protein degradation, molecular glues and CRISPR.
In the last 20 years or so, many new cancer treatments have emerged that provide greater precision and targeting of cancer cells.…